【摘要】 目的探讨恩度(重组人血管内皮抑制素)联合紫杉醇和卡铂靶向治疗晚期NSCLC患者的早期临床效果。方法 69例住院的晚期NSCLC患者随机分为观察组38例、对照组31例,疗程结束后按WHO恶性肿瘤疗效评定标准判定疗效。结果观察组患者胸部CT的瘤体中位直径治疗前较治疗后缩小了(2.74±0.24)cm,而对照组仅缩小(2.09±0.42)cm(P<0.05);观察组PR21例,SD14例,有效率为92.11%,对照组PR11例,SD7例,有效率为58.06%,观察组有效率显著高于对照组(P<0.01)。结论应用恩度联合紫杉醇和卡铂靶向治疗晚期NSCLC早期临床观察瘤体缩小明显,有效率和临床受益率明显高于对照组。更多还原

【Abstract】 Objective To study the early clinical effect of Endostar(recombinant human endostatin) combined with paclitaxel and carboplatin in the targeted treatment of advanced non-small cell lung cancer(NSCLC).Methods Sixty-nine cases of advanced NSCLC treated by Endostar combined with paclitaxel and carboplatin were divided into two groups:observation group(38 cases)and control group(31cases),After treatment,all the cases were assessed by using WHO standards for the efficacy of malignant tumors.Results In the observation group,the median diameter was reduced by(2.74±0.24)cm.And in the control group,it was reduced by(2.09±0.42)cm.The observation group showed 21 cases of PR and 14 cases of SD,with the effective rate of 92.11%.The control group showed 11 cases of PR and 7 cases of SD,with the effective rate of 58.06%.Conclusion Endostar combined with paclitaxel and carboplatin can reduce tumor size significantly in the targeted treatment of advanced(NSCLC,with significantly higher efficiency and clinical benefit rates).更多还原